(Press-News.org) PITTSBURGH, October 20, 2025 — Doctors and researchers at the University of Pittsburgh and UPMC have developed a new treatment for epilepsy patients who don’t respond to medication and aren’t candidates for surgery. Their approach, published today in Nature Communications, uses deep brain stimulation (DBS) that is tailored to each patient’s unique brain wiring.
Epilepsy affects more than 50 million people worldwide, and about a third of those do not respond to medication. For some, seizures are generated in parts of the brain that control essential functions – speech, movement or vision – that can’t be safely removed. Brain “pacemakers,” which send small electrical pulses into the center part of the brain called the thalamus, have helped some patients, but have had minimal effect on others.
“The existing FDA-cleared therapy targets only one portion of the thalamus, the anterior nucleus,” said lead author Arianna Damiani, M.Sc., a graduate student researcher at Pitt’s Rehab Neural Engineering Laboratories (RNEL). “We hypothesized that electrical stimulation of the brain would be more effective if we could target the specific area of the thalamus most strongly connected to the seizing areas of the cerebral cortex.”
The research team, whose members are physicians, neuroscientists and bioengineers, created detailed maps of the seizure activity of 41 patients with drug-resistant epilepsy. Using advanced imaging and brain recordings, researchers elucidated the brain connections between seizure-prone regions of patients’ cerebral cortex, the outermost layer of their brain, and various locations on the thalamus, a deep cerebral structure located in the topographic center of the head.
When the team electrically stimulated the area of the thalamus best matched with seizure activity in the cerebral cortex, patients experienced a dramatic decrease in the number and severity of seizures. In a group of patients who received long-term implants, those with personalized targeting had an average seizure reduction of nearly 90%. Some became seizure-free for months at a time.
“This is a major step toward making brain stimulation more effective for people with treatment-resistant epilepsy,” said Damiani. “This isn’t just a treatment, this is your treatment.”
This study was unique in that it combined multiple techniques – electrical stimulation, imaging and clinical assessment – within the same patient cohort. Prior research has largely focused on only one aspect.
“The epilepsy monitoring unit at UPMC Presbyterian is like few others in the world,” said coauthor Jorge Gonzalez-Martinez, M.D., Ph.D., UPMC neurosurgeon and director of the epilepsy surgery service. “This technology allowed us to create a novel framework for collecting and analyzing data that ultimately resulted in hyper-personalized treatments for our patients. The combination of high clinical expertise with cutting edge science is what makes significant clinical advancements possible.”
In the past, the Pitt/UPMC team has used thalamus-targeting DBS to restore arm mobility in patients with partial paralysis due to traumatic brain injury and stroke. Researchers think that this precise targeting approach could potentially be used to treat other conditions, including psychiatric disorders, such as depression or addiction.
“We’re understanding more and more about the common mechanisms underlying many conditions that originate in the brain,” said co-senior author Elvira Pirondini, Ph.D., also with RNEL. “With both stroke and epilepsy, we targeted an area deep in the brain that is connected to the motor cortex. The difference was whether we wanted to potentiate activity or suppress it.”
Additional co-authors include Sirisha Nouduri, Jonathan C. Ho, M.D., Steve Salazar, Aude Jegou, Jiahao Jay Chen, Eliza Reedy, Naoki Ikegaya, and Thandar Aung, M.D., all of Pitt, and Sridevi Sarma, Ph.D., of Johns Hopkins University.
This research received financial support from National Institutes of Health grants 1R01NS122927-01A1 and 1R01NS131428-01A1.
END
Personalized brain stimulation offers new hope for people with hard-to-treat epilepsy
2025-10-20
ELSE PRESS RELEASES FROM THIS DATE:
The tiny droplets that bounce without bursting
2025-10-20
If you’ve ever added liquid to a hot frying pan, maybe you noticed how the droplets bubbled up and skittered across the sizzling surface, rather than immediately flattening and wetting. This happens because the pan’s heat starts boiling the undersides of the droplets, producing vapor that acts as an insulating cushion on which they can – momentarily – dance.
Previously, scientists have produced a room-temperature version of this phenomenon – known as the Leidenfrost effect – ...
Immunotherapy after surgery shows promise in treating rare, aggressive skin cancer
2025-10-20
Note: Abstract #6267, titled ECOG-ACRIN EA6174: Surgically Treated Adjuvant Merkel Cell Carcinoma with Pembrolizumab, is scheduled to be presented during the European Society for Medical Oncology meeting on Monday, Oct. 20, at 2:30 a.m. ET in the Cologne Auditorium, Messe Berlin, Berlin.
A drug that harnesses the immune system to attack cancer cells has proved successful in preventing a rare and aggressive form of skin cancer from spreading to other organs when given immediately after surgery, a new study shows.
Led by researchers at NYU ...
Immunotherapy after surgery shows potential in preventing the spread of aggressive skin cancer
2025-10-20
A new cancer clinical trial by the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) shows that a drug that utilizes the body’s immune system to target and eliminate cancer cells appeared to reduce the risk of distant metastases for an aggressive form of skin cancer when given immediately after surgery, but did not significantly reduce the overall risk of recurrence, which was a co-primary endpoint of the trial. The randomized phase 3 STAMP trial (EA6174) is the largest clinical study to date evaluating pembrolizumab, ...
What is the extent of disparities in cancer clinical trials among low- and middle-income countries?
2025-10-20
New research reveals that the number and complexity of cancer clinical trials since 2001 have varied across low- and middle-income countries (LMICs), with economic growth contributing to disparities, but only to a certain extent. The findings are published by Wiley online in CANCER, a peer-reviewed journal of the American Cancer Society.
Although LMICs are expected to experience the greatest global burden of cancer in the coming years, cancer clinical trials are disproportionally concentrated in high-income countries. Because evidence suggests that LMICs have increased the number of cancer clinical trials over the last few decades, researchers investigated disparities ...
Invisible poison: Airborne mercury from gold mining is contaminating African food crops, new study warns
2025-10-20
In a recent study published today in the European Geosciences Union (EGU) journal Biogeosciences, scientists have confirmed that mercury pollution from artisanal and small-scale gold mining (ASGM) is contaminating food crops not through the soil, as previously believed, but directly from the air. Driven by the surging price of gold, which has increased by more than tenfold since 2000, the rapid expansion of unregulated mining in these regions raises urgent questions about food security, human health, and environmental justice
The study, conducted by an international team of scientists led by Excellent ...
Nearly half of Finns with chronic conditions find medication therapy a burden
2025-10-20
According to a recent study, 44% of people with chronic conditions who responded to a population-based survey experienced medication-related burden (MRB). The burden was most common among people with diabetes, heart disease, rheumatic disease or some other musculoskeletal disorder. The greatest burden was caused by factors associated with health care, such as fragmented care and the cost of medicines, as well as adverse drug reactions or concerns about them.
“Other factors linked with MRB were poor health status, limits on functional capacity and low income,” says Pharmacist and Doctoral Researcher Heidi Mikkola from the School of Pharmacy at the University of ...
Do animals fall for optical illusions? What fish and birds can teach us about perception
2025-10-20
Have you ever looked at two circles of exactly the same size and sworn one was larger? If so, your eyes have been tricked by the Ebbinghaus illusion, a classic example of how context can shape what we see. Place a circle among other smaller circles, and it seems bigger; place it among larger ones, and it shrinks before our eyes. This illusion fascinates psychologists because it reveals that perception is not a mirror of the outside world but a clever construction of the brain.
But here is the question that inspired our study: do other animals fall for the same tricks? If a tiny fish or a bird perceives ...
New guideline emphasizes conversations about mood, mental health between patients and clinicians
2025-10-20
Depression is a mental illness, and support for depression can improve emotions, thoughts, and well-being. A new guideline from the Canadian Task Force on Preventive Health Care recommends that patients aged 18 and older talk to their health care providers about depression rather than undergo routine screening with standard tools, like questionnaires. The guideline is published in CMAJ (Canadian Medical Association Journal) https://www.cmaj.ca/lookup/doi/10.1503/cmaj.250237.
In Canada, depression is common, with about 1 in 10 people (without bipolar disorder) experiencing depression in their lifetimes. It negatively affects how a person ...
Children’s Hospital of Philadelphia researchers observe significant reduction in diagnosis of food allergies following expert guidelines encouraging early peanut exposure
2025-10-20
Philadelphia, October 20, 2025 – Peanuts represent one of the most common causes of immunoglobulin E (IgE)-mediated, or anaphylactic, food allergies in children, yet a landmark study found that early introduction of peanut to infants may lower their risk of developing this allergy. Now, a new study from researchers from Children’s Hospital of Philadelphia (CHOP) has shown that the rates of diagnosis of peanut and other IgE-mediated food allergies have declined since the adoption of guidelines encouraging early introduction practices.
The findings, published today ...
ESMO 2025: VT3989 continues to show promising early results in patients with advanced mesothelioma
2025-10-19
VT3989 is a first-in-class YAP-TEAD inhibitor from Vivace Therapeutics that is currently in Phase I/II trials for patients with advanced solid tumors, with a focus on refractory mesothelioma
In this trial, VT3989 demonstrated notable antitumor activity, with a disease control rate of 86% at the clinically optimized dosing levels
These data provide the first clinical proof-of-concept for effectively drugging the Hippo-YAP-TEAD pathway
VT3989 was awarded Orphan Drug Designation and Fast Track Designation for the treatment of mesothelioma by the FDA
BERLIN, OCTOBER 19, 2025 ― The first-in-class YAP-TEAD inhibitor ...